1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsRolling/annual application cycles; 2025 application process ongoing per page.
Technology Development Investment Fund (TDIF) is sponsored by Memorial Sloan Kettering Cancer Center. Grant supporting early-stage development of MSK inventions with strong commercialization potential, including AI and cloud technology projects.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Technology Development Investment Fund | Memorial Sloan Kettering Cancer Center Ready to start planning your care? Call us at 646-926-0945 to make an appointment.
Technology Development Investment Fund The TDIF program, among many measures of success, has advanced technologies to more than 30 industry partnerships and successful startups, generating valuable dollars that help MSK fuel future research and support our institutional mission. Dr. Anaeze (Anii) Offodile and Dr. Christopher Klebanoff at an event celebrating the 15th anniversary of MSK’s Technology Development Investment Fund.
The Technology Development Investment Fund (TDIF) One challenge for innovators at MSK and elsewhere is that technology development is costly and funding options are limited—especially once the potential for federal grant funding has been exhausted. Industry partnerships have often been significant in helping to advance MSK technologies.
From an institutional perspective, however, it can be advantageous to find ways to further development internally before the OTD team pursues licenses or collaborations with external partners. One important strategy in addressing crucial gap funding needs is MSK’s Technology Development Investment Fund (TDIF), created in 2009 to provide early-stage investment for MSK inventions and initiatives with strong commercialization potential.
The TDIF is administered by OTD, which is responsible for managing the commercialization of MSK innovation. For MSK’s community of innovators, TDIF investment can make the difference between their ability to progress their technologies—or not.
The TDF program, among many measures of success, has advanced technologies to more than 30 industry partnerships and successful startups, generating valuable dollars that help MSK fuel future research and support our institutional mission. New : A new program under TDF launched in 2025. The ai TDIF program is a specifically dedicated track for MSK projects that substantially rely on AI or cloud technology.
MSK Innovation by the Numbers $30M TDIF investments to date 65+ MSK projects have received TDIF investments 30+ Industry partnerships and startups involving TDIF projects 2 FDA approved drugs from TDIF projects Reach out to our technology transfer and business development experts Technology Development Investment Fund (large-scale projects) TDIF investments deliver essential funding and support to MSK innovators, helping transform promising ideas into practical solutions and advancing MSK's mission to lead in groundbreaking research.
The TDIF program awards up to $500,000 over a two-year period. Projects may be appropriate for TDIF funding at various stages of development. Early-stage TDF projects might generate in vivo survival data, or the construction of a device prototype.
Later-stage TDIF projects might lead to pre-clinical animal toxicology data to support an IND application, or involve activities necessary to meet Chemistry, Manufacturing, and Controls (CMC) requirements for new drug products. MSK innovators also may apply for support for a Phase 1 clinical trial or for drug manufacturing, including scale-up and formulation.
Expanding upon the TDIF program’s success, MSK launched a sister program in 2022 known as the flex TDIF. It provides up to $200,000 in institutional investment for smaller-scale research projects that might take up to a year to complete, along with the same type of internal and external advisory guidance that has proven so valuable in the original TDF program.
Typically, 8-10 innovation projects with strong commercialization potential receive flex TDIF awards yearly. To date, MSK has invested nearly $4. 5 million in 30 flex TDIF projects and the 2025 application process is ongoing.
Supporting Innovation at MSK for 15 Years MSK’s TDF program launched in 2009 to provide essential “gap” funding for MSK inventions and initiatives with the potential for future commercialization and public availability. Administered by MSK’s Office of Technology Development (OTD), the TDF program has played an invaluable role in supporting innovation at the institution.
Showcasing TDIF Successes Widely acknowledged as a dedicated source of support for the brilliant innovators in our community, the TDIF enables them to catalyze their ideas into impactful realities. This impact extends beyond financial support, as it directly fosters an environment and culture where pioneering ideas can thrive.
Anaeze Offodile II, MD, MPH MSK’s Chief Strategy Officer My lab develops advanced computational algorithms for medical imaging and video data analysis. TDIF has been crucial in supporting our work across pathology and surgery. In pathology, it enabled clinical integration, validation, regulatory approval, partnerships with commercial vendors, and securing major federal grants like the seven-year NCI MERIT Award.
In surgery, TDIF helped develop cutting-edge real-time video analysis AI models, deploy them in the operating room, and validate them on complex procedures. Assistant Attending, Computer Science, MSK
According to the current listing, eligibility includes: Small businesses and researchers with MSK inventions. Confirm the full requirements in the official notice before applying.
The current listing shows up to $500,000 over two years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Technology Development Investment Fund (TDIF) is funded by Memorial Sloan Kettering Cancer Center. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article